Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

ODAC Votes Against Risk:Benefit Profile of Frontline PD-1 Inhibitors in HER2–, MSS Gastric/GEJ Adenocarcinoma With a PD-L1 Expression Under 1

September 26th 2024

The FDA’s ODAC voted against the risk:benefit profile of PD-1 inhibitors in first-line advanced gastric/GEJ adenocarcinoma with a PD-L1 of less than 1.

Genitourinary Oncologists Break Down Data from Lesser-Known Studies at the 2024 ESMO Congress

September 26th 2024

Oncology experts share their key takeaways in genitourinary cancers and recent updates from the 2024 ESMO Congress.

Experts Share Intriguing Early-Phase Sarcoma Studies From the 2024 ESMO Congress

September 25th 2024

Read about the early-phase sarcoma studies presented at the 2024 ESMO Congress that experts are keeping their eyes on.

FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial Sarcoma

September 23rd 2024

Dr Warner discusses the FDA approval of afami-cel for patients with advanced synovial sarcoma and key findings from the pivotal SPEARHEAD-1 trial.

BDTX-1535 Generates Early Signals of Antitumor Activity in R/R EGFR+ NSCLC

September 23rd 2024

BDTX-1535 yielded durable clinical activity in patients with relapsed/refractory, EGFR-mutant NSCLC harboring resistance mutations.

CINtec PLUS Receives WHO Endorsement in Cervical Cancer Prevention Guidelines

September 23rd 2024

The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.

NDA Resubmitted for Camrelizumab Plus Rivoceranib in Unresectable HCC

September 23rd 2024

An NDA seeking the approval of camrelizumab plus rivoceranib for the frontline treatment of patients with unresectable HCC has been resubmitted to the FDA.

First-Line Serplulimab Receives Positive CHMP Opinion for ES-SCLC

September 23rd 2024

The CHMP has recommended the European approval of serplulimab for the first-line treatment of extensive-stage small cell lung cancer.

QOL Benefits With Nivolumab, Challenges with Sacituzumab Govitecan Characterize Bladder Cancer Management Updates

September 23rd 2024

Guru Sonpavde, MD, expands on findings from 2 key bladder cancer trials presented at the 2024 ESMO Congress.

Zolbetuximab Plus Chemotherapy Wins EU Approval for Advanced CLDN18.2+ Gastric/GEJ Cancer

September 20th 2024

The European Commission has approved frontline zolbetuximab plus chemotherapy for advanced, CLDN18.2-positive gastric and GEJ cancer.

Narmafotinib Earns FDA Fast Track Designation for Advanced Pancreatic Cancer

September 20th 2024

The FDA has granted fast track designation to narmafotinib for the treatment of advanced pancreatic cancer.

Pembrolizumab-Based Regimens Earn Positive CHMP Opinion in Endometrial and Cervical Cancers

September 20th 2024

The CHMP has issued positive opinions for 2 pembrolizumab-based regimens for select patients with endometrial and cervical cancers.

CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer

September 20th 2024

The EMA’s CHMP has recommended the marketing authorization of mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian cancer.

Dr Andre on the Efficacy of Nivolumab/Ipilimumab in MSI-H/dMMR mCRC Subgroups

September 16th 2024

Thierry Andre, MD, discusses subgroup and safety analyses of the phase 3 CheckMate 8HW trial of frontline nivolumab plus ipilimumab in MSI-H/dMMR mCRC.

FDA Approval Insights: Epcoritamab in Relapsed/Refractory Follicular Lymphoma

September 16th 2024

Jennifer Crombie, MD, shares insights about the FDA's approval of epcoritamab for patients with relapsed/refractory follicular lymphoma.

Dr Popat on OS Outcomes With Amivantamab Plus Chemotherapy in EGFR-Mutated, Advanced NSCLC

September 16th 2024

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses OS data with amivantamab plus chemotherapy in EGFR-mutated, advanced NSCLC after progression on osimertinib.

Dr Choueiri on Lessons Learned from the TiNivo-2 Study in Metastatic RCC

September 15th 2024

Toni Choueiri, MD, discusses findings with tivozanib plus nivolumab in metastatic RCC after progression on an immune checkpoint inhibitor.

Dr Secord on Mirvetuximab Soravtansine in Platinum-Sensitive, FRα-High Ovarian Cancer

September 15th 2024

Angeles A. Secord, MD, MHSc, discusses the PICCOLO trial of mirvetuximab soravtansine in recurrent, platinum-sensitive, FRα-high ovarian cancer.

Dr Lin on the Efficacy of T-DXd in HER2+ Advanced Breast Cancer With CNS Metastases

September 14th 2024

Nancy U. Lin, MD, discusses the DESTINY-Breast12 trial of T-DXd in patients with HER2-positive metastatic breast cancer with or without brain metastases.

Dr Girard on Nivolumab Plus Relatlimab and Chemotherapy in Stage IV or Recurrent NSCLC

September 14th 2024

Nicolas Girard, MD, discusses the RELATIVITY-104 trial of nivolumab plus relatlimab and chemotherapy in previously untreated stage IV or recurrent NSCLC.